Navigation Links
Cardium Reports on First Quarter 2008 Highlights and Financial Results
Date:5/9/2008

$(6,734,128) $(5,839,849)

Net loss per common share - basic

and diluted $(0.16) $(0.17)

Weighted average shares outstanding

- basic and diluted 42,709,247 34,362,080

Selected Condensed March 31, December 31,

Consolidated Balance Sheet 2008 2007

(unaudited) (audited)

Cash and cash equivalents $6,300,638 $7,722,816

Accounts receivable, net 311,837 565,613

Inventories, net 1,337,870 1,037,164

Prepaid expenses and other current

assets 657,820 522,067

Property and equipment, net 1,644,416 1,650,632

Patented technology and intangibles,

net 4,568,916 4,766,330

Other long-term assets 748,023 661,067

Total assets $15,569,520 $16,925,689

Total current liabilities $5,545,073 $5,255,392

Long-term liabilities 2,849,334 3,241,992

Stockholder's equity 7,175,113 8,428,305

Total liabilities and stockholder's

equity $15,569,520 $16,925,689


'/>"/>
SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
2. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
3. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
4. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
5. Cardium Completes $5.3 Million Registered Direct Offering
6. Cardium Announces $5.3 Million Registered Direct Offering
7. Novavax Reports First Quarter 2008 Financial Results
8. Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
9. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
10. Pharmos Corporation Reports 2008 First Quarter Results
11. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015 HUYA Bioscience International (HUYA) today announced ... Japan Society of HTLV-1, held this week at the ... of the Society is to promote research on HTLV-1 ... medical technology and research related to these fields to ... "HUYA is proud to support this prestigious conference," said ...
(Date:8/27/2015)... ... August 27, 2015 , ... Proove Biosciences, a ... the relationship of genetics and hypertension at the International Academy of Cardiology ... British Columbia, Canada. The event, which boasts an extensive overview of the latest ...
(Date:8/26/2015)... MIAMI , Aug. 26, 2015  The ... at the University of Miami Miller School of ... its clinical trial to test for the first ... was successfully completed.  This FDA approved Phase I/II ... islet transplantation and is an important first step ...
(Date:8/26/2015)... After litigating and negotiating patent infringement ... P2i United States patent RE43,651 (the ... the United States without any admission or ... party. As a result of the parties, settlement, the US ... dismissed the case without prejudice. Under ...
Breaking Biology Technology:HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4P2i Settles United States Litigation 2
... NEOG ) announced today that its revenues for the ... 2.2% from the previous year,s second quarter to $44,891,000. Net ... compared to the prior year,s second quarter net earnings of ... the first six months of fiscal year 2012 increased to ...
...  HistoRx recently licensed from Yale University a new clinical ... doctors treating patients with melanoma to identify a subset ... in their lymph nodes, have a 40% risk of ... quantitative IHC testing method that enables measurement of protein ...
... 21, 2011 Acumen Pharmaceuticals announces today the ... Merck & Co., Inc.) of a 2003 agreement, ... exclusive worldwide rights to develop and commercialize anti-ADDL ... Merck,s decision to discontinue this anti-ADDL ...
Cached Biology Technology:Neogen Reports Second Quarter Results 2Neogen Reports Second Quarter Results 3Neogen Reports Second Quarter Results 4Neogen Reports Second Quarter Results 5Neogen Reports Second Quarter Results 6HistoRx Licenses Melanoma Assay from Yale University 2Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimer's Disease From Merck 2
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
(Date:7/31/2015)... La 10 th International Conference on Genomics ... 22 al 25 de octubre de 2015 en ... conferencia celebra su décimo aniversario. Desde su inauguración en el ... reuniones anuales más influyentes del mundo en el campo ,ómico, ... y mejores a nivel científico. ICG-10 se ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... a highly detailed picture of marine conditions and the ... according to international experts convening a landmark conference in ... at the meeting aim to throw open a large, ... worldwide the work of two pioneering North America-based programs ...
... method that could drastically change the way we purify ... DHV engineering bureau, has developed a compact and environmentally-friendly ... sink quickly. An important part of the project's success ... who, on Tuesday, 27 June, will receive her PhD ...
... peer microscopically into the closest freshwater pond, you'd hesitate ... probably notice an oddly furry, pear-shaped organism gliding along--and ... tiny predator has a big name-- Tetrahymena thermophila --and ... organism for research into how cells work. , Scientists ...
Cached Biology News:Creating a window on 'oceans in motion' 2Creating a window on 'oceans in motion' 3Creating a window on 'oceans in motion' 4Delft water-purification method promises radical improvement 2What's shaped like a pear and has 2 genomes? Check the pond 2What's shaped like a pear and has 2 genomes? Check the pond 3
... AFFINITY PURIFIED GOAT ANTI-MOUSE ... is conjugated with highly ... The antibody has ... human, rat, fetal bovine, ...
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
...
Contains L-glutamine....
Biology Products: